

October 4, 2017

IMMUDYNE™

ImmuDyne Announces New CFO to Take Company through Next Phase of Growth

NEW YORK, Oct. 04, 2017 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) ("ImmuDyne" or the "Company"), a leader in the development and online marketing of OTC health and wellness products addressing large unmet needs, today announced Robert Kalkstein will be joining the company as Chief Financial Officer.

As CFO of ImmuDyne, Robert will be responsible for ensuring the finance organization can support ImmuDyne's aggressive growth plans both at present and in the future.

"Robert brings a strong background to our finance team from his experience in audit, banking and as CFO at several emerging growth companies where he successfully provided the financial strategy and leadership to help the organizations get to the next level of growth," said Mark McLaughlin, president and CEO, ImmuDyne. "With Robert, I'm confident we'll be well positioned to meet our goals of consistent profitable growth moving forward. We're excited to have him on the ImmuDyne team."

Previously Robert held positions at Peerless System Corp., Jefferies & Co. and PricewaterhouseCoopers. He has more than 10 years of experience in the areas of accounting, finance, SEC compliance and operations. Mr. Kalkstein is a CPA and received a Bachelor of Engineering in Biomedical Engineering and a Masters of Engineering in Engineering Management at Stevens Institute of Technology in Hoboken, NJ.

"I am both honored and excited to be a part of ImmuDyne at this time," said Robert Kalkstein. "I am impressed with ImmuDyne's growth over the past 24 months and believe there is a big opportunity ahead. I look forward to contributing to the success of the Company."

About ImmuDyne

ImmuDyne, Inc. (the "Company") is a health and wellness company that develops, manufactures, and markets innovative consumer products. ImmuDyne manufactures and markets a proprietary and patent protected Yeast Beta Glucan that has been shown in thousands of clinical studies to support and regulate the human immune system. It has broad applications in skincare and as an immune support supplement. ImmuDyne PR, a majority owned subsidiary of ImmuDyne, Inc., is the digital marketing arm of ImmuDyne and is currently focused on marketing products for thicker and fuller hair (Shapiro MD) and a skincare line containing ImmuDyne's proprietary Yeast Beta Glucan ingredient (Inate MD). All of ImmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com

Forward-Looking Statements

Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer:

Forward looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to ImmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

The preliminary, unaudited information provided above is based on the Company's current estimate of results from operations for the second quarter and its cash at June 30, 2017, and remains subject to change based on the Company's closing procedures, including the subsequent occurrence or identification of events prior to the formal issuance of the quarterly financial statements.

Investor Relations Contact:
ImmuDyne, Inc.
Bernard Girma +1-949-215-7754

Source: ImmuDyne, Inc.